News

Under the collaboration, funds managed by Blackstone Life Sciences (BXLS) will provide $329.1m (€300m) to speed up the pivotal studies as well as clinical development programme for a

The company’s application for the investigational, oral small molecule potassium-competitive acid blocker vonoprazan is based on the positive results announced earlier from its pivotal Phase III PHALCON-EE trial.

Incyte noted that the latest move comes after the acceptance and priority review of its sNDA for the cream in December last year. The FDA has extended the

An advanced PARP inhibitor, Lynparza is the first targeted treatment which is being developed by the companies to exploit DNA damage response (DDR) pathway deficiencies to kill cancer

Erasca’s ERAS-007 is currently being evaluated alone or in combination with different inhibitors to upstream MAPK pathway nodes as part of the MAPKlamp strategy. Under the collaboration, Lilly

An autologous TCR-T cell treatment, NTLA-5001 is intended to target the Wilms’ Tumor (WT1) antigen, which is highly expressed in AML and several other hematologic and solid tumours.

The company sought approval for the combination therapy to treat previously untreated mantle cell lymphoma (MCL) adult patients not suitable for autologous stem cell transplantation (ASCT). Jointly developed

The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to

A drug-free nasal spray, Bentrio is designed for personal protection against airborne viruses and allergens. It forms a protective gel layer on the nasal mucosa upon application into